Arbutus Reports Second Quarter 2019 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Arbutus Biopharma (ABUS) Misses Q2 EPS by 7c
August 5, 2019 7:37 AM EDTArbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.46), $0.07 worse than the analyst estimate of ($0.39).
Appointed William Collier, with decades of leadership experience in antivirals, President & CEOAnnounced preliminary Phase 1a/1b clinical trial results demonstrating that AB-506 is a potent capsid inhibitor... More